Cowan A, Doxey JC, Harry EJ. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol. 1977;60(4):547–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cowan A, Lewis JW, Macfarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol. 1977;60(4):537–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Samways DSK. Clarifying intrinsic efficacy, partial agonism, and full agonism: the case of buprenorphine. Br J Anaesth. 2024;132(2):431–2.

Article  CAS  PubMed  Google Scholar 

Cowan A. Buprenorphine: new pharmacological aspects. Int J Clin Pract Suppl. 2003;133:3–8 (discussion 23-4).

CAS  Google Scholar 

Davis MP, Davies A, McPherson ML, Reddy A, Paice JA, Roeland E, et al. Opioid analgesic dose and route conversion ratio studies: a scoping review to inform an eDelphi guideline. Support Care Cancer. 2024;32(8):542.

Article  PubMed  Google Scholar 

Kogel B, Christoph T, Strassburger W, Friderichs E. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. Eur J Pain. 2005;9(5):599–611.

Article  PubMed  Google Scholar 

Leng X, Li Z, Lv H, Zheng Y, Liu Y, Dai K, et al. Effectiveness and safety of transdermal buprenorphine versus sustained-release tramadol in patients with moderate to severe musculoskeletal pain: an 8-week, randomized, double-blind, double-dummy, multicenter, active-controlled, noninferiority study. Clin J Pain. 2015;31(7):612–20.

Article  PubMed  Google Scholar 

Naing C, Aung K, Racloz V, Yeoh PN. Safety and efficacy of transdermal buprenorphine for the relief of cancer pain. J Cancer Res Clin Oncol. 2013;139(12):1963–70.

Article  CAS  PubMed  Google Scholar 

Wolff RF, Aune D, Truyers C, Hernandez AV, Misso K, Riemsma R, et al. Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. Curr Med Res Opin. 2012;28(5):833–45.

Article  CAS  PubMed  Google Scholar 

Magnelli F, Biondi L, Calabria R, Fiore A, Peluso E, Vonella D, et al. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study. Clin Drug Investig. 2010;30(Suppl 1):21–6.

Article  CAS  PubMed  Google Scholar 

Poulain P, Denier W, Douma J, Hoerauf K, Samija M, Sopata M, et al. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain. J Pain Symptom Manag. 2008;36(2):117–25.

Article  CAS  Google Scholar 

Likar R. Transdermal buprenorphine in the management of persistent pain - safety aspects. Ther Clin Risk Manag. 2006;2(1):115–25.

CAS  PubMed  PubMed Central  Google Scholar 

Varey NC. The safety of buprenorphine (Temgesic). N Z Med J. 1990;103(882):24.

CAS  PubMed  Google Scholar 

Aguilar B, Penm J, Liu S, Patanwala AE. Efficacy and safety of transdermal buprenorphine for acute postoperative pain: a systematic review and meta-analysis. J Pain. 2023;24(11):1905–14.

Article  CAS  PubMed  Google Scholar 

Barutell C, Camba A, Gonzalez-Escalada JR, Rodriguez M, Opioid Group of the Spanish Society for the Study of P. High dose transdermal buprenorphine for moderate to severe pain in spanish pain centres—a retrospective multicenter safety and efficacy study. Pain Pract. 2008;8(5):355–61.

Article  PubMed  Google Scholar 

Bridge TP, Fudala PJ, Herbert S, Leiderman DB. Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. Drug Alcohol Depend. 2003;70(2 Suppl):S79-85.

Article  CAS  PubMed  Google Scholar 

Canneti A, Luzi M, Di Marco P, Cannata F, Pasqualitto F, Spinoglio A, et al. Safety and efficacy of transdermal buprenorphine and transdermal fentanyl in the treatment of neuropathic pain in AIDS patients. Minerva Anestesiol. 2013;79(8):871–83.

CAS  PubMed  Google Scholar 

Frost M, Bailey GL, Lintzeris N, Strang J, Dunlop A, Nunes EV, et al. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder. Addiction. 2019;114(8):1416–26.

Article  PubMed  PubMed Central  Google Scholar 

Hale M, Urdaneta V, Kirby MT, Xiang Q, Rauck R. Long-term safety and analgesic efficacy of buprenorphine buccal film in patients with moderate-to-severe chronic pain requiring around-the-clock opioids. J Pain Res. 2017;10:233–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hazle MC, Saxon AJ, Hill KP. Buprenorphine in safety-sensitive positions. Am J Drug Alcohol Abuse. 2022;48(3):255–9.

Article  PubMed  Google Scholar 

Kamei J, Saitoh A, Suzuki T, Misawa M, Nagase H, Kasuya Y. Buprenorphine exerts its antinociceptive activity via mu 1-opioid receptors. Life Sci. 1995;56(15):PL285–90.

Article  CAS  PubMed  Google Scholar 

Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55(5):569–80.

Article  CAS  PubMed  Google Scholar 

Bhivandkar S, Sarfraz Z, Jain L, Bachu A, Malo PK, Hsu M, et al. Therapeutic potential of buprenorphine in depression: a meta-analysis of current evidence. J Clin Med Res. 2024;16(2–3):46–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manag. 2005;29(3):297–326.

Article  CAS  Google Scholar 

Del Pozo B, Atkins D, Andraka-Christou B, Wightman R, Clark MH, Huynh P, et al. Buprenorphine involvement in opioid overdose deaths: a retrospective analysis of postmortem toxicology in Marion County, Indiana, 2015–2021. Drug Alcohol Depend Rep. 2023;6:100131.

Article  PubMed  PubMed Central  Google Scholar 

Villiger JW, Taylor KM. Buprenorphine: high-affinity binding to dorsal spinal cord. J Neurochem. 1982;38(6):1771–3.

Article  CAS  PubMed  Google Scholar 

Villiger JW, Taylor KM. Buprenorphine : characteristics of binding sites in the rat central nervous system. Life Sci. 1981;29(26):2699–708.

Article  CAS  PubMed  Google Scholar 

Boas RA, Villiger JW. Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br J Anaesth. 1985;57(2):192–6.

Article  CAS  PubMed  Google Scholar 

Bidlack JM, Knapp BI, Deaver DR, Plotnikava M, Arnelle D, Wonsey AM, et al. In vitro pharmacological characterization of buprenorphine, samidorphan, and combinations being developed as an adjunctive treatment of major depressive disorder. J Pharmacol Exp Ther. 2018;367(2):267–81.

Article  CAS  PubMed  Google Scholar 

Zamani N, Buckley NA, Hassanian-Moghaddam H. Buprenorphine to reverse respiratory depression from methadone overdose in opioid-dependent patients: a prospective randomized trial. Crit Care. 2020;24(1):44.

Article  PubMed  PubMed Central  Google Scholar 

Zamani N, Hassanian-Moghaddam H. Intravenous buprenorphine: a substitute for naloxone in methadone-overdosed patients? Ann Emerg Med. 2017;69(6):737–9.

Article  PubMed  Google Scholar 

Zamani N, Hassanian-Moghaddam H, Bayat AH, Haghparast A, Shadnia S, Rahimi M, et al. Reversal of opioid overdose syndrome in morphine-dependent rats using buprenorphine. Toxicol Lett. 2015;232(3):590–4.

Article